What is driving the increase in Vertex's R&D expenses?

The significant increase in R&D expenses is primarily driven by intensified clinical development efforts for the company's core drug candidates: VX-950 for Hepatitis C, VX-702 for Rheumatoid Arthritis, and VX-770 for Cystic Fibrosis. The adoption of new stock-based compensation accounting standards (FAS 123(R)) also contributed to higher reported R&D expenses.

How has the adoption of FAS 123(R) impacted Vertex's financial reporting?

The adoption of FAS 123(R) on January 1, 2006, requires Vertex to expense the fair value of employee stock options and other stock-based compensation over the service period. This resulted in a substantial increase in stock-based compensation expense to $8.1 million in Q1 2006, compared to $1.0 million in Q1 2005. While this increases reported expenses and net loss, the company views it as a more accurate reflection of the cost of its equity awards.

What is the company's current financial outlook and liquidity position?

Vertex anticipates continued net losses for the foreseeable future, projecting a loss of $205-$225 million for 2006. However, the company expects revenues to be in the range of $210-$235 million for 2006. Vertex maintains a strong liquidity position, with $378.8 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2006, providing ample resources to fund its ongoing development activities.

Are there any significant updates on Vertex's drug development pipeline?

Yes, Vertex is advancing its key programs. Phase II trials for VX-950 and VX-702 are progressing with positive preliminary results. The company also plans to initiate clinical development for VX-770 in the second quarter of 2006. Furthermore, Merck has commenced a Phase II clinical trial for VX-680, an Aurora-kinase inhibitor for cancer, in which Vertex has an interest.

VRTX 10-Q Quarterly Report Q1 FY2006 — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals reported its first quarter 2006 results, showing a notable increase in total revenues driven by higher royalty payments and expanded collaborative research and development revenues. Despite the revenue growth, the company's net loss widened due to significantly increased investment in research and development, particularly for its core drug candidates VX-950 (HCV), VX-702 (RA), and VX-770 (cystic fibrosis). This increased R&D spending, coupled with the adoption of new stock-based compensation accounting standards (FAS 123(R)), contributed to a higher reported net loss and a significant increase in stock-based compensation expense. The company also provided financial guidance for the full year 2006, projecting continued losses but also substantial revenue, and maintained a strong cash position.

Key Highlights

1Total revenues increased by approximately 36% to $39.1 million in Q1 2006 compared to $28.6 million in Q1 2005, driven by higher royalties and collaborative R&D revenue.
2Research and Development (R&D) expenses surged by 31% to $75.2 million in Q1 2006, reflecting increased investment in core drug candidates VX-950, VX-702, and VX-770.
3The company adopted new stock-based compensation accounting standards (FAS 123(R)) starting January 1, 2006, leading to a substantial increase in reported stock-based compensation expense to $8.1 million in Q1 2006 from $1.0 million in Q1 2005.
4Net loss for the quarter was $50.1 million ($0.47 per share) compared to $44.7 million ($0.56 per share) in the prior year period, with the improved EPS driven by a higher weighted average share count.
5Vertex Pharmaceuticals has a robust cash position, with $81.8 million in cash and cash equivalents and $257.6 million in marketable securities as of March 31, 2006.
6The company reiterated its 2006 financial guidance, expecting revenues between $210-$235 million and a net loss between $205-$225 million.
7Key clinical development programs are advancing, including Phase II trials for VX-950 and VX-702, and the upcoming initiation of clinical development for VX-770.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2006

Summary

Key Highlights

Frequently Asked Questions